• LAST PRICE
    11.5400
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    11.0000/ 1
  • Ask / Lots
    11.5600/ 2
  • Open / Previous Close
    12.2900 / 11.5400
  • Day Range
    Low 11.5300
    High 12.2900
  • 52 Week Range
    Low 7.5200
    High 20.2000
  • Volume
    229,756
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 12.28
TimeVolumeNRIX
09:32 ET238112.29
09:33 ET10012.26
09:39 ET10012.2537
09:42 ET10012.12
09:44 ET20012.09
09:46 ET10011.97
10:00 ET40012.01
10:06 ET25012.04
10:15 ET20011.92
10:18 ET240012.02
10:27 ET20011.98
10:29 ET20011.93
10:40 ET10011.82
10:44 ET10011.81
10:47 ET10011.79
10:51 ET290011.835
10:54 ET30011.81
10:56 ET10011.77
10:58 ET30011.73
11:02 ET110011.72
11:03 ET10011.7
11:05 ET59211.7
11:09 ET160011.68
11:12 ET10011.68
11:14 ET10011.66
11:16 ET10011.62
11:18 ET40011.655
11:20 ET63811.71
11:21 ET30011.66
11:23 ET80011.66
11:25 ET70011.59
11:30 ET40011.6
11:32 ET10011.66
11:36 ET90011.6
11:41 ET10011.59
11:43 ET60011.6
11:50 ET348211.6
11:57 ET10011.63
11:59 ET20011.63
12:01 ET1928511.775
12:03 ET70011.72
12:06 ET34611.68
12:10 ET10011.65
12:12 ET41211.6892
12:14 ET10011.66
12:17 ET10011.62
12:21 ET56011.635
12:24 ET10011.68
12:26 ET10011.67
12:32 ET60011.76
12:33 ET10011.77
12:35 ET70011.71
12:46 ET89411.57
12:48 ET10011.57
12:51 ET52711.65
12:53 ET25211.63
12:55 ET79311.67
12:57 ET20011.71
01:04 ET23311.75
01:09 ET20011.77
01:11 ET20011.78
01:13 ET91111.74
01:18 ET30011.71
01:20 ET40011.75
01:22 ET160011.79
01:24 ET10011.79
01:27 ET80011.73
01:29 ET30011.785
01:31 ET40011.755
01:33 ET10011.73
01:36 ET50011.7
01:40 ET100011.66
01:47 ET20011.67
01:49 ET30011.67
01:51 ET10011.67
01:54 ET105411.64
02:00 ET85111.63
02:02 ET40011.64
02:03 ET60011.67
02:05 ET50011.7
02:09 ET20011.75
02:12 ET60711.75
02:14 ET131811.79
02:20 ET80011.88
02:21 ET60011.83
02:25 ET10011.83
02:27 ET260011.805
02:30 ET60011.79
02:34 ET10011.775
02:36 ET120011.74
02:38 ET60011.76
02:41 ET20011.77
02:43 ET310011.7
02:48 ET10011.725
02:50 ET20011.725
02:52 ET125911.66
02:57 ET157511.72
02:59 ET30011.76
03:01 ET60011.7
03:03 ET269211.675
03:06 ET160011.67
03:08 ET10011.68
03:10 ET83911.65
03:12 ET51311.665
03:14 ET145011.61
03:15 ET30011.64
03:17 ET40011.64
03:19 ET150011.63
03:21 ET40011.66
03:24 ET40011.67
03:26 ET40011.68
03:28 ET50011.655
03:30 ET60011.67
03:32 ET10011.69
03:33 ET40011.65
03:35 ET114711.615
03:37 ET50011.62
03:39 ET20011.62
03:42 ET110011.65
03:44 ET70011.7
03:46 ET148011.67
03:48 ET171511.625
03:50 ET137211.63
03:51 ET70011.66
03:53 ET132511.595
03:55 ET315011.55
03:57 ET394511.55
04:00 ET6542511.54
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNRIX
Nurix Therapeutics Inc
544.1M
-3.1x
---
United StatesTNGX
Tango Therapeutics Inc
541.4M
-5.3x
---
United StatesZYME
Zymeworks Inc
567.7M
-2.5x
---
United StatesARCT
Arcturus Therapeutics Holdings Inc
519.0M
-3.5x
---
United StatesATRA
Atara Biotherapeutics Inc
478.2M
-2.0x
---
United StatesRPTX
Repare Therapeutics Inc
522.4M
-16.9x
---
As of 2023-02-09

Company Information

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other challenging diseases. It leverages its DELigase, an integrated discovery platform to identify and advance drug candidates targeting E3 ligases. Its drug candidate includes NX-2127, NX-5948, NX-1607, DeTIL-0255, KINASE-CTM3, COVID-CTMs, LIGASE-INH2 and DeCART. Its lead drug candidate, NX-2127, is an orally available Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies. Its lead drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. Its KINASE-CTM3, a kinase involved in T cell growth and activation to treat T cell malignancies and autoimmune disease.

Contact Information

Headquarters
1700 Owens St Ste 205SAN FRANCISCO, CA, United States 94158-0006
Phone
415-660-5320
Fax
415-525-4200

Executives

Independent Chairman of the Board
David Lacey
President, Chief Executive Officer, Director
Arthur Sands
Chief Financial Officer
Hans Van Houte
Chief Operating Officer, Executive Vice President - Product Development
Stefani Wolff
Chief People Officer
Eric Schlezinger

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$544.1M
Revenue (TTM)
$39.2M
Shares Outstanding
47.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-3.71
Book Value
$7.66
P/E Ratio
-3.1x
Price/Sales (TTM)
13.9
Price/Cash Flow (TTM)
---
Operating Margin
-441.21%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.